Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives.

Détails

ID Serval
serval:BIB_3F3EE764A453
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives.
Périodique
Frontiers in cell and developmental biology
Auteur⸱e⸱s
Faes S., Demartines N., Dormond O.
ISSN
2296-634X (Print)
ISSN-L
2296-634X
Statut éditorial
Publié
Date de publication
2021
Peer-reviewed
Oui
Volume
9
Pages
636037
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies.
Mots-clé
HIF-α, angiogenesis, mTOR, rapalogs, renal cell carcinoma
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/04/2021 18:08
Dernière modification de la notice
20/04/2021 6:34
Données d'usage